Contemporary Management of Gastrointestinal Cancers: From Molecular Profiling to Multidisciplinary Care

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 42 Minutes

Overview

This activity provides an update on the contemporary management of gastrointestinal malignancies, emphasizing molecular profiling, biomarker-directed treatment, and multidisciplinary care. Participants will review the use of tissue and liquid biopsy, immunohistochemistry, and next-generation sequencing to guide treatment selection across colorectal, esophagogastric, pancreatic, hepatocellular, and biliary tract cancers. The program will address evolving systemic therapies, including immunotherapy, targeted therapy, anti-HER2 agents, CLDN18.2-targeted therapy, PARP inhibitors, and chemotherapy-based regimens, with attention to treatment selection, safety, and integration into clinical practice

Learning Objectives

  1. Discuss the importance of molecular profiling and tailoring therapy in gastrointestinal malignancies
  2. Describe the importance of a multidisciplinary care in gastrointestinal malignancies
  3. Identify current treatment options in patients with colorectal, gastric cancer and hepatobiliary tumors
  4. Describe the safety of novel therapies and integration into practice

Target Audience:

This activity is intended for oncology nurse practitioners, physician assistants, nurses, clinical pharmacists, and other healthcare providers involved in the care of patients with cancer.

 

Presented By

                                                                  

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
09/29/2026
Course expires: 
10/05/2027
Cost:
$0.00
Rating: 
0

Faculty

Syma Iqbal, MD

Associate Professor of Clinical Medicine
Section Head - Gastrointestinal Oncology
Medical Director Ambulatory/Infusion and Inpatient Services NCH
Norris Comprehensive Cancer Center at Keck School of Medicine of USC
Los Angeles, CA

Syma Iqbal, MD graduated from the Keck School of Medicine of USC in 1995 and completed a Hematology and Oncology Fellowship in 2001. She is currently an Associate Professor in the Division of Oncology at the Keck School of Medicine/Norris Comprehensive Cancer Center and Section Chief of Gastrointestinal Oncology. She is the Associate Cancer Physician in Chief for USC Norris Comprehensive Cancer Center and Keck Medicine of USC and serves as Medical Director of both Ambulatory/Infusion and Inpatient Services for Norris Cancer Hospital.

Currently, Dr. Iqbal Chairs the Norris Clinical Investigations Committee. Dr. Iqbal is also an accomplished clinical researcher and has led and participated in trials for gastrointestinal malignancies. She is a national thought leader in the systemic therapy of esophageal and gastric cancer, and her national leadership posts include serving as co-Chair of the Southwest Oncology Group Esophago-Gastric Committee and Chair of the National Cancer Institute’s Esophago-Gastric Task Force.

Dr. Sundhar Ramalingam is involved in clinical trials done through Duke University.  Clinical trials are designed to provide patients with access to the newest possible treatments. He is also part of our multi-disciplinary cancer team, including urologic oncologists, geneticists, radiation oncologists, pathologists, radiologists, and other specialists. Dr. Ramalingam grew up in Cary and did all of his medical training in the Research Triangle Park area. He feels honored to practice in the same community I have lived in for more than twenty-five years. 

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.


Syma Iqbal, MD  declares the following financial relationships:

Advisory (All ended): BeOne, Cardiff Onc, Exelixis, Jazz
Consultant: Merck, AstraZeneca
Speakers Bureau: Astellas (ended)

Other Contributors:

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Access to internet required

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above